DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for GM1 gangliosidosis type 3 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleGM1 gangliosidosis type 3 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for gm1 gangliosidosis type 3 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
galactosidase beta 1 (GLB1) — GLB1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2r,3s,4r,5sdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3THD · 1.79 Å · ligand (2R,3S,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol (DGJ). Experimental structure, not a prediction.
What the evidence adds up to
A 2022 phase IIb open-label trial of N-acetyl-l-leucine (NALL) in 20 patients with GM2 gangliosidoses (Tay-Sachs and Sandhoff diseases) reported a statistically significant improvement on the primary anchor test (8-Meter Walk Test or 9-Hole Peg Test) after six weeks of treatment compared to baseline, with a p-value of 0.039. Secondary measures of ataxia and clinical global impression also improved. No serious adverse reactions occurred. The trial enrolled patients aged six years and older, used a six-week washout period, and had blinded central raters for the primary outcome. The study provides Class IV evidence. No trial of NALL in GM1 gangliosidosis has been published.
GM1 gangliosidosis type 1 is a distinct, severe disease. A 2015 case report describes a 15-month-old girl with global developmental delay, seizures, respiratory failure, and brain MRI showing delayed myelin maturation and a small corpus callosum. Peripheral blood film showed 54% lymphocytes with prominent cytoplasmic vacuoles; leukocyte beta-galactosidase activity was low, confirming the diagnosis. A separate 2015 case report notes extensive Mongolian spots present from birth in a 9-month-old boy with GM1 gangliosidosis type 1. A 1987 case describes a typical fatal course before age two with severe respiratory distress, diagnosed by deficient beta-galactosidase in leucocytes and urinary oligosaccharides. A 2010 case report states that adult manifestation of GM1 gangliosidosis is rare, with only a few case reports in the literature.
No treatment trial for GM1 gangliosidosis type 3 is reported in these abstracts. The natural history of type 3 is not described here. What is missing is any clinical trial data for NALL or any other drug in GM1 gangliosidosis type 3, adequate patient numbers to power a trial in this ultra-rare adult-onset form, and validated outcome measures sensitive to the slow progression of type 3.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Neurology · 2022 · 39 citations · open access
Efficacy and Safety of N-Acetyl- <scp>l</scp> -Leucine in Children and Adults With GM2 Gangliosidoses
AbstractBACKGROUND AND OBJECTIVES: GM2 gangliosidoses (Tay-Sachs and Sandhoff diseases) are rare, autosomal recessive, neurodegenerative diseases with no available symptomatic or disease-modifying treatments. This clinical trial investigated N-acetyl-l-leucine (NALL), an orally administered, modified amino acid in pediatric (≥6 years) and adult patients with GM2 gangliosidoses. METHODS: In this phase IIb, multinational, open-label, rater-blinded study (IB1001-202), male and female patients aged ≥6 years with a genetically confirmed diagnosis of GM2 gangliosidoses received orally administered NALL for a 6-week treatment period (4 g/d in patients ≥13 years, weight-tiered doses for patients 6-12 years), followed by a 6-week posttreatment washout period. For the primary Clinical Impression of Change in Severity analysis, patient performance on a predetermined primary anchor test (the 8-Meter Walk Test or the 9-Hole Peg Test) at baseline, after 6 weeks on NALL, and again after a 6-week washout period was videoed and evaluated centrally by blinded raters. Secondary outcomes included assessments of ataxia, clinical global impression, and quality of life. RESULTS: = 0.039), as well as secondary measures of ataxia and global impression. NALL was safe and well tolerated, with no serious adverse reactions. DISCUSSION: Treatment with NALL was associated with statistically significant and clinically relevant changes in functioning and quality of life in patients with GM2 gangliosidosis. NALL was safe and well tolerated, contributing to an overall favorable risk:benefit profile. NALL is a promising, easily administered (oral) therapeutic option for these rare, debilitating diseases with immense unmet medical needs. TRIAL REGISTRATION INFORMATION: The trial is registered with ClinicalTrials.gov (NCT03759665; registered on November 30, 2018), EudraCT (2018-004406-25), and DRKS (DRKS00017539). The first patient was enrolled on June 7, 2019. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that NALL improves outcomes for patients with GM2 gangliosidoses.
American Journal of Clinical Pathology · 2015 · 2 citations · open access
Vacuolated Lymphocytes on Peripheral Blood Film Examination in the Diagnosis of GM1 Gangliosidosis: Case Report
AbstractGM1 gangliosidosis is an autosomal recessive lysosomal storage disease caused by mutation of the GLB1 gene (3p22.3) encoding for β-galactosidase and characterized by accumulation of ganglioside substrates in lysosomes. Its prevalence is estimated to be approximately 1 in 100,000 to 200,000 live births. Prognosis is very poor, with life expectancy rarely exceeding two years. The examination of peripheral blood films for vacuolated lymphocytes can be used as a first-line screening in patients with a history suggestive of lysosomal storage diseases. We report the case of a 15-month-old girl with global developmental delay who had normal development until age 6 months, when she began social, gross motor, and fine motor milestone regression of unknown etiology. She presented with new-onset seizures and respiratory failure. Brain MRI revealed delayed myelin maturation, small corpus callosum and dilated CSF spaces. Serum chemistry indicated hepatic insult with elevated transaminases and low albumin. Peripheral blood film examination revealed 54% lymphocytes, most of which had numerous, prominent, small, cytoplasmic vacuoles. Vacuolated lymphocytes in the peripheral blood in this clinical context suggested a metabolic storage disease. Leukocytes were analyzed for lysosomal enzymes and showed low β-galactosidase activity, diagnostic of GM1 gangliosidosis. Vacuolated lymphocytes are best visualized at the thin end of the peripheral blood film. Evaluation of peripheral blood films is rapid and cost effective, and permits the identification of vacuolated lymphocytes; this finding raises the suspicion for lysosomal storage diseases. In this case, pathologist identification of vacuolated lymphocytes on the peripheral blood smear provided the most important diagnostic information, indicating that a lysosomal storage disease must be excluded. In the appropriate clinical context, identification of vacuolated lymphocytes on peripheral blood smear is a critical finding that may indicate the presence of a previously undiagnosed lysosomal storage disease.
International Journal of Contemporary Pediatrics · 2015 · 0 citations · open access
Large Mongolian spots in GM1 gangliosidosis
AbstractA 9-month old male child with GM1 gangliosidosis type 1 presented with Mongolian spots. The cutaneous lesions were present since birth before the appearance of the other features of the disease. Our patient, whose clinical course and physical signs were in keeping with GM1 gangliosidosis, had extensive Mongolian blue spots and this adds to the evidence supporting such an association.
Arquivos de Neuro-Psiquiatria · 1987 · 0 citations · open access
GM1 - type 1 glanglio sido sis: anatomo-clinic study of a case
AbstractThe observation of generalized GM1 gangliosidosis type 1 (Norman-Landing disease) is reported. The case is typical, featuring all the main clinical and biological signs of the disease. Diagnosis was established by the demonstration of a severe deficit in beta-galactosidase activity in leucocytes, by the demonstration of oligosaccharides in the urine, and by the histological examination after the fatal outcome before the age of two with severe respiratory distress.
The adult manifestation of GM1-Gangliosidosis – a case report
AbstractIntroduction: The GM1-gangliosidosis is a lysosomal storage disease caused by a defect of beta galactosidase. Due to the enzyme defect, an accumulation of GM1 gangliosid occurs preferably in the central nervous system (CNS). Whereas the disease manifestation is typically seen in childhood, there are only few case reports of adult manifestation.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
